Emcure Pharmaceuticals shares surged 4% after the company reported robust Q4 FY25 earnings. As of 2:50 PM, the shares were trading 4.70% higher at Rs 1,124.10.
For the quarter ended March 31, 2025, Emcure posted a 63% year-on-year (YoY) jump in net profit at ₹197.2 crore, compared to ₹121 crore in Q4 FY24. Revenue from operations rose 19.4% YoY to ₹2,116.2 crore, up from ₹1,771.4 crore in the same period last year.
EBITDA grew 29.7% to ₹402 crore, with the EBITDA margin expanding to 19.01% from 17.5%, reflecting improved efficiency and cost control. Total income came in at ₹2,120.7 crore, while expenses rose to ₹1,849.7 crore, largely due to higher procurement and employee costs.
For the full financial year FY25, Emcure reported revenue of ₹7,896 crore, up from ₹6,658 crore in FY24. Net profit rose 34% YoY to ₹707.4 crore from ₹527.6 crore last year.
The company credited its performance to strong growth in domestic and international markets, a better product mix, and strategic investments in R&D and new product launches.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
